Common Contracts
2 similar Master Collaboration Agreement contracts by Kymera Therapeutics, Inc.
SECOND AMENDMENT TO MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • February 22nd, 2024 • Kymera Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Second Amendment to Master Collaboration Agreement (this “Second Amendment”) is made and entered into as of October 21, 2021 (the “Second Amendment Effective Date”), by and between and Vertex Pharmaceuticals Incorporated (“Vertex”) and Kymera Therapeutics, Inc. (“Company”), and amends that certain Master Collaboration Agreement (the “Agreement”), dated as of May 9, 2019 by and between Vertex and Company, as amended by that certain First Amendment to Master Collaboration Agreement, dated as of August 27, 2020. All capitalized terms used, but not otherwise defined, in this Second Amendment shall have the meaning given to them in the Agreement.
SECOND AMENDMENT TO MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • February 23rd, 2023 • Kymera Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Second Amendment to Master Collaboration Agreement (this “Second Amendment”) is made and entered into as of October 21, 2021 (the “Second Amendment Effective Date”), by and between and Vertex Pharmaceuticals Incorporated (“Vertex”) and Kymera Therapeutics, Inc. (“Company”), and amends that certain Master Collaboration Agreement (the “Agreement”), dated as of May 9, 2019 by and between Vertex and Company, as amended by that certain First Amendment to Master Collaboration Agreement, dated as of August 27, 2020. All capitalized terms used, but not otherwise defined, in this Second Amendment shall have the meaning given to them in the Agreement.
